Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial

Leukemia. 2017 Mar;31(3):734-738. doi: 10.1038/leu.2016.317. Epub 2016 Nov 2.

J Edelmann^{1

2}, E Tausch¹, D A Landau^{3

4

5

6}, S Robrecht⁷, J Bahlo⁷, K Fischer⁷, A M Fink⁷, J Bloehdorn¹, K Holzmann⁸, S Böttcher⁹, L Werner¹⁰, M Kneba⁹, J G Gribben², D S Neuberg¹⁰, C J Wu³, M Hallek⁷, H Döhner¹, S Stilgenbauer¹

¹ Internal Medicine III, Ulm University, Ulm, Germany.
² Barts Cancer Institute, Queen Mary University of London, London, UK.
³ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA.
⁴ Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.
⁵ Division of Hematology and Medical Oncology and The Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA.
⁶ New York Genome Center, New York, NY, USA.
⁷ Internal Medicine I, University of Cologne, Cologne, Germany.
⁸ Center for Clinical Research, Genomics Core Facility, Ulm University, Ulm, Germany.
⁹ Second Department of Medicine, University Hospital of Schleswig-Holstein, Campus Kiel, Kiel, Germany.
¹⁰ Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, USA.

No abstract available

Publication types